Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with ...

I was self-conscious about having tardive dyskinesia symptoms in my first job after my last hospitalization. However, I got ...

Medically reviewed by Nicholas R. Metrus, MD Tardive dyskinesia and dystonia are both neurological disorders that can affect ...

A team led by UT Southwestern Medical Center researchers has uncovered the atomic structure of a protein complex pivotal to ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric ...

Tremors, stiffness, and slowed movement are classic signs of Parkinson's disease. Learn more about the signs and symptoms of Parkinson's disease.

A team led by UT Southwestern Medical Center researchers has uncovered the atomic structure of a protein complex pivotal to ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan ...

Tiny fat bubbles carrying gene therapy have successfully repaired DNA in the lungs and liver of animals with alpha-1 antitrypsin deficiency—a promising leap toward treating humans with this rare ...

Laycock underwent the procedure last year and recently received an upgrade to adaptive deep brain stimulation (ADBS), which ...

On June 25, 2025 and June 30, 2025, Supernus and Sage, respectively, filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust ...

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Neurocrine Biosciences (NasdaqGS:NBIX) with a ...